B-cell chronic lymphocytic leukemia (CLL), the most common leukemia in older adults, remains largely incurable and novel treatments are urgently required. We previously reported powerful pro-apoptotic actions of bezafibrate (BEZ) and medroxyprogesterone acetate (MPA) against Burkitts lymphoma cells. Here, we demonstrate that BEZ and MPA individually, and more potently when combined (BEZ þ MPA), induce apoptosis of unsorted and CD19 þ ve -selected CLL cells and abrogate the pro-proliferative activity of CD40 L . This action was tumor cell specific, as the drugs had little impact on normal donor cells. The antiproliferative actions of BEZ þ MPA were associated with the generation of reactive oxygen species (ROS), and the proapoptotic actions were associated with the generation of both ROS and mitochondrial superoxide (MSO). BEZ increased prostaglandin D 2 (PGD 2 ) synthesis by CLL cells, and treatment with PGD 2 and its antineoplastic derivative 15dD 12,14, PGJ 2 recapitulated BEZ-induced antiproliferative and proapoptotic actions. The PGD 2 receptor antagonist, BW868C, did not block BEZ or PGD 2 activity against CLL cells. The potency of BEZ þ MPA against CLL cells mirrored that of chlorambucil, and BEZ þ MPA combined with chlorambucil was more potent than either treatment alone. Given the known safety profiles of BEZ and MPA, our data warrant further investigation of their potential as novel therapy for CLL.
Introduction
B-cell chronic lymphocytic leukemia (CLL) is the most common form of leukemia in older adults with a median age at diagnosis of 65 years and the majority of patients are over 65 years by the time treatment is necessary. 1, 2 It is heterogeneous to the degree that many patients never need treatment, whereas others die of progressive disease within a few years despite treatment.
Notwithstanding recent improvements in the understanding of the biology of CLL, it remains a challenging disease. For many decades, chemotherapy has been primarily based on DNA, alkylating agents such as chlorambucil, a drug that is well tolerated and effective at palliating CLL in many patients. Using low-dose chlorambucil, the combined partial response and complete response rates range from 45 to 86% and higher response rates have been reported with higher doses. 2 The use of combination regimens incorporating alkylating agents, corticosteroids, anthracyclines and steroids have failed to show significant improvements in progression-free survival or overall survival and are associated with increased toxicity. 2 Over the last two decades a number of trials have shown an improvement in response rates initially using fludarabine alone but more recently using fludarabine/cyclophosphamide combinations with or without rituximab. 3, 4 However, the median age of patients recruited to these trials is typically less than 65 years and regimens such as fludarabine/cyclophosphamide/rituximab are not well tolerated in patients over the age of 70 years. The MD Anderson Cancer Center, University of Texas reported fludarabine/cyclophosphamide/rituximab as first-line therapy in patients 470 years of age and showed that 75% of patients experienced grades 3-4 myelosuppression, 11% experienced grades 3-4 infection and fewer than half were able to complete the 6 cycles of induction. 5, 6 A recent meta-analysis involving five trials with 1838 randomized patients supports the argument that greater response rates are achievable by using purine antagonists such as fludarabine but highlights that this carries with it a greater risk of toxicity. 7 The study found no conclusive evidence that treatment with purine antagonists improves survival.
Thus, although there have been improvements in responses in CLL, it remains incurable for the vast majority of patients and there is a need for novel treatments with acceptable toxicity. Also, given the heterogeneity of disease progression, eradicating minimal residual disease may be a reasonable aim for fitter patients or patients with high-risk disease, 8 whereas palliation may be the best approach for a significant proportion of CLL patients.
In this study, we have evaluated the in vitro efficacy of two common, well tolerated drugs, bezafibrate (BEZ) and medroxyprogesterone acetate (MPA) that have been used in clinical practice for several decades. BEZ is a lipid-lowering agent that mediates its activity as a ligand of the nuclear receptor PPARa and MPA is an orally active contraceptive progestogen. The study was based on our previous experience in Burkitts lymphoma 9 and acute myeloid leukemia (AML) [10] [11] [12] (Khanim et al., 2008, unpublished data). We show that both BEZ and MPA induce apoptosis in primary CLL cells and that the combination BEZ þ MPA is significantly more proapoptotic than either agent alone. Similarly, BEZ, MPA and more so BEZ þ M-PA also exerted marked antiproliferative effects against CD40-Ligand (CD40 L )-stimulated primary CLL cells. Inhibition of proliferation was associated with the accumulation of reactive oxygen species (ROS), whereas apoptosis was associated with elevated ROS and mitochondrial superoxide (MSO). As observed in our studies of AML cells, BEZ and BEZ þ MPA treatments elevated prostaglandin D 2 (PGD 2 ) production. Importantly, both PGD 2 and its downstream bioactive derivative 15deox-yD 12, 14 PGJ 2 (15dD 12, 14 PGJ 2 ) also caused ROS-associated growth inhibition and ROS-and MSO-associated apoptosis. Finally, we demonstrate that the actions of BEZ, MPA and BEZ þ MPA enhance the chlorambucil sensitivity of primary CLL cells.
Patients and methods

Patients and donors
Unselected patients with B-cell CLL attending the outpatient clinic at Birmingham Heartlands Hospital were recruited to the study. The patients had been diagnosed according to the standard morphologic, immunophenotypic and clinical criteria 2 and had provided informed written consent for the study which had received local ethical approval. Normal donors were recruited following informed consent. Primary mononuclear cells were prepared using Ficoll Paque-Plus (Amersham, Bucks., UK) and Leucosep tubes (Greiner Bio-one, Gloucester, Gloucestershire, UK). When indicated in the text, CD19-positive (CD19 þ ve ) cells were purified from the mononuclear fraction by positive selection using anti-CD19 microbeads and passing through MS columns (Miltenyi Biotec, Surrey, UK) according to the manufacturer's instructions. The resultant isolated mononuclear/CD19 þ ve cells were seeded and cultured as below.
Cell culture using L cells
Murine L cells, stably transfected with plasmids encoding CD40 L (CD40 L -L cells), as described previously 13 as well as non-transfected L cells, a gift from Professor John Gordon, were maintained in RPMI 1640 medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum and 1% penicillin-streptomycin (all Invitrogen Ltd, Paisley, UK). To inhibit growth, cells were treated with medium containing 0.02 mg/ml mitomyocin C (Sigma, Poole, Dorset, UK) for 3 h, trypsinized and frozen in large batches for subsequent experimental use as supporting cells. For co-culture, cells were thawed and seeded at 10 4 per well in 96-well plates for flow cytometry based assays and 5 Â 10 5 per well in 6-well plates for larger scale analyses.
Mononuclear cells or CD19
þ ve cells were seeded on to the stromal L cells, at 10 5 per well in 96-well plates or 5 Â 10 6 per well in 6-well plates, in RPMI 1640 with 10% fetal bovine serum and 1% penicillin-streptomycin and 1 ng/ml IL-4 (R&D systems, Abingdon, Oxford, UK), while treated as described in the text. Before analysis, the cells were removed from the stromal cells by pipetting. To ensure that all the patient cells had been recovered, that the stroma was still intact and that no CLL cells were under the stromal surface, all plates were observed by phase-contrast microscopy.
Soluble CD40-ligand
Human soluble CD40-Ligand (sCD40-L), fused with a linker peptide and a FLAG-tag at the N terminus, together with an enhancer (both Alexis Biochemicals, Bingham, Nottinghamshire, UK) was used to try to recapitulate the actions of CD40 L stroma. Both soluble CD40 L and the enhancer were reconstituted according to the manufacturer's instructions and stored at À20 1C. RPMI containing 5% ITS þ (BD, Oxford, Oxfordshire, UK) alone or supplemented with 2 mg/ml of both sCD40-L and enhancer was plated into 96-well plates (100 ml per well) and left at room temperature for 30 min. CLL cells were seeded into the pre-filled wells at 10 4 per well in 50 ml and allowed to settle overnight before treatment. At 48 h post-sCD40-L exposure, duplicate wells were pooled and incubated with 2 ml mouse anti-CD23 (FITC) antibody (BD) for 20 min at room temperature. Cells were washed in phosphate-buffered saline (PBS) and fixed in 500 ml FACS fix (2% (v/v) fetal bovine serum, 1% (v/v) formaldehyde in PBS) and analyzed by flow cytometry on a BD FACS Calibur utilizing Cell Quest Pro software (BD).
Treatments
A concentration of 1000 Â stocks of 0.5 M BEZ in dimethylsulfoxide (DMSO), 5 mM MPA in ethanol and 10 000 Â stocks of 10 mM chlorambucil in ethanol (all from Sigma) were stored at À20 1C. PGD 2 and 15dD 12, 14 PGJ 2 (Affiniti) were dissolved in DMSO to yield 1000 Â stocks (50 and 35 mM, respectively) and stored at À20 1C. 1000 Â stock of 1 mM GW 9662 (Cayman Chemicals, Tallinn, Estonia) was made in DMSO. The supplied 21.8 mM BW 868C (Cayman Chemicals) was diluted to 100 mM in PBS. Before experimental use, stocks were diluted to a working concentration of 4 Â in RPMI 1640 medium and added to the wells in 50 ml volumes. For PGD 2 receptor antagonist experiments, cells were pre-treated overnight with 100 nM BW 868C. All treatments were set in triplicate with controls containing the highest concentration of carrier solvent used in the corresponding treatments.
Assessment of cell proliferation
3 H-Thymidine (Amersham, Bucks., UK) was diluted in RPMI 1640 to 20 mCi. For the final 12-16 h of culturing, 2 mCi was added to each well followed by freezing at À20 1C. Thawed plates were harvested on to filter mats (Wallac, Waltham, MA, USA) using a Skatron instrument and read on a Betaplate Scintillation counter.
Assessment of apoptosis by JC-1, annexin V, cell cycle and caspase cleavage All analyses were carried out by flow cytometry on a BD FACS Calibur utilizing Cell Quest Pro software (BD). 5,5 0 ,6, 6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethylbenzimidazolylcarbocyanine iodide (JC-1; Sigma) was dissolved at 1 mg/ml in DMSO and stored at À20 1C. Following treatment, CLL cells from triplicate wells were transferred from the stroma, pooled and incubated with 2.5 mg/ml JC-1 at 37 1C for 30 min, before analysis. Annexin V positivity was assessed using the annexin V FITC kit (BD) on pooled triplicate wells, according to manufacturer's instructions. Cell cycle was analyzed by pooling triplicate wells and adding 500 ml cell cycle buffer (10 mg/ml propidium iodide, 10 À4 M sodium chloride, 1% Triton X-100 in distilled water) to the cell pellet. Caspase cleavage was analyzed using Caspatag, a pan-caspase assay Kit (Chemicon, Watford, Herts., UK) on pooled wells according to the manufacturer's instructions. Staurosporin treatment (1 mM) was carried out as a positive control for each patient sample.
Assessment of accumulation of ROS and MSO
Reactive oxygen species was measured using Carboxy-H 2 DCFDA (Molecular Probes, Paisley, UK), which was dissolved in DMSO to yield a 2000 Â stock and was stored under nitrogen at À20 1C. Immediately before use, a 5 mM working dilution was made in warm PBS. The media in each well was replaced with 200 ml of the working stock and incubated at 37 1C for 40 min. Following incubation, appropriate wells were pooled and analyzed by flow cytometry (emission wavelength 517-527 nm). MitoSOX Red (Molecular Probes) was used to assess the presence of MSO on pooled triplicate wells, according to the manufacturer's instructions, before analysis by flow cytometry (emission wavelength 580 nm).
Western blot
Total proteins (40 mg) were separated by SDS-polyacrylamide gel electrophoresis on gels containing 10% polyacrylamide (Geneflow, Fradley, Staffs., UK) and transferred to PVDF Immobilon-P membrane (Millipore Corp, Watford, Herts., UK). Membranes were blocked overnight with 5% (w/v) nonfat milk powder (Marvel, Wisbech, Cambs., UK) in Trisbuffered saline Tween-20 (TBS-T), briefly washed and probed with a 1 in 10 000 dilution of AKR1C3 (Sigma) antibody in 5% (w/v) non-fat milk powder in Tris-buffered saline Tween-20 for 1 h. Following washing in TBS-T, membranes were probed with anti-mouse antibody (Sigma) diluted 1 in 1000 as above, for 45 min. Signal was developed using Supersignal West Pico Chemiluminescent substrate (Pierce, Cramlington, Northumberland, UK). Autorads were exposed for 10 min. Equal loading was 
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Real-time PCR quantification
Reactions were performed using an ABI Prism 7700 sequence detector (Applied Biosystems, Foster City, CA, USA 
PGD 2 enzyme-linked immunosorbent assay
Cells were treated in six-well plates on stroma for 8 h. Subsequently, cells were harvested with 1 ml of supernatant removed before centrifugation. Cell pellets were resuspended in appropriate retained medium followed by homogenization using a Precellys 24 ceramic bead-based homogenization system (Omni International Marietta, GA, USA). Cell homogenates were incubated on ice for 5 min with 1 ml ice-cold acetone before centrifugation at 3000 g for 20 min. Supernatant was removed and kept on ice. A further 0.5 ml ice-cold acetone was added to homogenized pellet followed by further centrifugation. The subsequent supernatant was pooled with that from the first centrifugation step and kept at À80 1C until use. Prostaglandins were extracted using C18 reverse phase extraction columns (Chromabond, Anachem, Luton, Beds., UK) and all assay-specific reagents for Prostaglandin D 2 -MOX EIA kit (Cayman Chemicals) were prepared and prostaglandin levels were determined according to the manufacturer's instructions.
Analysis of PGD 2 metabolism by thin layer chromatography
Chronic lymphocytic leukemia samples were cultured as 200 ml cultures in 96-well plates at 1 Â 10 7 cells per well in PBS, with 0.2 mCi of 3 H-PGD 2 (Amersham) for 9 h. Prostanoids were extracted from the supernatant by the addition of 0.5 ml methanol (Fisher, Loughborough, Leicestershire, UK) and 2.5 ml 10%(v/v) formic acid (Sigma) and vortexing, before the addition of 1 ml of chloroform and 50 ml 4.2% (w/v) KCL (Sigma). Proteinaceous and aqueous layers were removed by aspiration following centrifugation in a Mistral 4L, at 2500 r.p.m. for 10 min. The remaining fraction was evaporated to dryness under a stream of nitrogen before being redissolved in 70 ml methanol and applied to Silica gel Thin Layer Chromatography plates (Fluka, Poole, Dorset, UK). Prostanoids were separated using chloroform, methanol, glacial acetic acid (Sigma) and distilled water (90:8:1:0.8), run at room temperature for approximately 2 h and, once dry, were read on a Bioscan AR-2000 plate reader. The migration of prostanoids was identified by their co-migration with known standards as revealed by incubation in iodine vapor.
Statistical analysis
Data are reported as mean values and their standard deviation or standard error of the mean as stated. One-factor within subjects' analysis of variance was used to assess drug responses. Homogeneity of variance was assessed by the Mauchly sphericity test. When data sets significantly violated this requirement, the Greenhouse-Geissler test was used to calculate a more conservative P-value for each F-ratio. Partial eta-squared (Z p 2 ) was used to measure the size of the statistical association, and pairwise comparisons were adjusted according to the Bonferroni method.
Several CLL prognostic factors were analyzed for their association with in vitro drug responses using the Mann-Whitney test. Drug responses were measured as drug/ control ratios. CLL prognostic factors included Binet stage (A vs B/C), lymphocyte doubling time (o vs 412 months), ZAP-70 expression (negative vs positive), CD38 expression (negative vs positive), IgVH mutation status (mutated vs unmutated) and cytogenetics (normal vs abnormal). Statistical analyses were performed using SPSS, version 14. 
CD5
Àve B cells, purified from healthy donors (n ¼ 4), were cultured on non-CD40 L -expressing stroma and treated with carrier control, 5 mM MPA, 5 mM BEZ or the combination for 24 h. Samples were analyzed for the binding of AV and uptake of PI using flow cytometry. Total AV staining was calculated by adding the events in the LR with those in the UR. In the absence of CD40 L, BEZ and MPA induced dosedependent increases in apoptosis as measured by acquired annexin V (AV) staining and loss of ability to exclude propidium iodide ( Figure 1a) . As previously observed for Burkitts lymphoma, apoptosis induced by MPA essentially plateaued beyond 5 mM. A similar level of apoptosis was observed in response to 0.5 mM BEZ and most subsequent experiments used 5 mM MPA and 0.5 mM BEZ either as single agents or in combination. The pertinence of these doses for potential in vivo treatment of CLL is addressed in the discussion. Again, as observed in our previous study of Burkitts lymphoma, combined BEZ and MPA (BEZ þ MPA) generated higher levels of apoptosis than either agent alone (Figure 1b) . Importantly, neither agent nor the combination induced AV reactivity nor increased propidium iodide uptake in CD5 
CD19
þ ve B cells from healthy donors was greater than that seen by the majority of CLL samples. This proliferation was attenuated by BEZ and MPA, however; considerable proliferation was maintained even in the presence of both drugs (Figure 2c ). To rule out the possibility that effects of BEZ, MPA or BEZ þ MPA were due to effects on the stroma rather than direct effects on the CLL cells, samples (n ¼ 3) were cultured without stromal L cells in IL-4 and ITS+ containing medium and in the presence or absence of soluble CD40 L (sCD40 L ). The apoptotic response observed in the absence of sCD40 L mirrored that observed when cells were (Figure 3a) . Thus, the sCD40 L used in the experiments was bioactive. In the absence of the proliferative response, sCD40 L -treated CLL cells remained sensitive to the proapoptotic activity of BEZ þ MPA (Figure 3a) . These data suggest that the delivery of CD40 L at the surface of L-3 cells provides a more powerful survival and proliferative signal than sCD40 L but again indicate that the actions of BEZ þ MPA are mediated directly at patients' cells. For this reason we continued to use the co-culture assays.
The majority of experiments utilized CLL mononuclear cells but in a subset of experiments we tested the action of BEZ and MPA against CLL cells positively selected for CD19 expression. As shown in Figure 3b , the basal levels of AV-positive cells in CD19 þ ve cultures were greater than in unpurified controls. However, the apoptotic response of CD19 sorted cells to the drugs was similar to that of unpurified cells (n ¼ 5). CD19 Patient parameters were 57% male and 43% female of which the median age was 67.5 years (range 29-90), with 71% at stage A and 29% at stage B at diagnosis. Lymphocyte doubling time, below 12 and over 12 months was equal (48 and 52%, respectively). CD38 expression was 68% negative, 14% positive and 18% not analyzed. ZAP-70 was measured in 54% and the ratio of negative to positive was equal. Genetic analysis revealed 46% were normal, 4% were ATM, 4% trisomy, 7% other and 39% not assessed. Fifty four percent had mutated IgVH and 14% unmutated, 32% were not assessed. In the case of induced apoptosis, the box plot analysis indicates significant increases caused by both drugs when used alone, but particularly by the drug combination (Figure 3c, left panel) . Mauchly sphericity tests identified that homogeneity of covariance could not be assumed, thus requiring the more conservative variant Greenhouse-Geisser test. Nonetheless, this test was highly significant (Po0.001) as was conventional analysis of variance indicating that the drug effects were real. Furthermore, the partial Z 2 red was calculated as 0.582 (40.1), indicating that the drug effects were also genuinely large.
Having confirmed the global effect of the treatments on apoptosis, pair-wise comparisons identified that BEZ, MPA and BEZ þ MPA increased apoptosis compared to controls (P ¼ 0.001, P ¼ 0.002 & Po0.001 respectively). There was no overall difference in apoptosis induction by either BEZ or MPA (P ¼ 1) but the combination was more effective than either drug alone (both Po0.001). It is important to note that within these samples the responses displayed by individuals varied qualitatively. Whilst some samples displayed responses that typified the summated response depicted by the box plot, others seemed to show apparent synergy; with the individual drugs having minimal effects and the combination giving a large effect. In a few samples neither the single drugs nor the combination had much effect on apoptosis. Figure 3c shows similar box plots for the inhibition of cell proliferation of CD40 L -stimulated CLL cells from 27/28 of the same samples analyzed above (one sample yielded too few cells for both types of analysis). Despite, the great range in CD40 L -stimulated proliferation, the response data were also strongly significant. The Greenhouse-Geisser test (Po0.001) and Z p 2 0.326 (40.1), indicated that the drug effects were also genuine and large. Bonferroni adjusted pairwise comparisons, identified that proliferation following BEZ, MPA and BEZ þ MPA treatments was significantly less than in untreated controls (P ¼ 0.011, 0.042 and 0.003, respectively). The antiproliferative effect of BEZ was not statistically different from that of MPA (P ¼ 0.199) but the combined treatment was significantly more antiproliferative than either BEZ or MPA alone (P ¼ 0.007 and 0.003, respectively).
BEZ treatment of primary CLL cells increases PGD 2 synthesis
Our studies in AML have identified that the actions of BEZ and MPA are associated with the synergistic accumulation of PGD 2 (Khanim et al., submitted 2008). In these cells, this accumulation was most probably through BEZ-induced oxidative stress 14, 15 and subsequently increased PGD 2 synthesis by the lipid peroxidation-dependent isoprostane pathway; 16 whereas MPA acted to inhibit the subsequent metabolism of PGD 2 by the aldo-ketoreductase AKR1C3. In contrast, in this study in CLL cells, only BEZ and BEZ þ MPA treatment of both non-CD40 Lstimulated and stimulated-CLL cells resulted in PGD 2 accumulation (Figure 4a ). MPA neither resulted in PGD 2 elevation when used alone nor enhanced accumulation of PGD 2 in response to BEZ. PGD 2 has two known routes to affect cell behavior. First directly by acting via cell surface PGD 2 receptors (DP1/DP2) and second by giving rise to 15dD 12,14 PGJ 2 which has multiple activities including acting as a ligand for PPARg. We therefore combined BEZ, MPA and BEZ þ MPA treatments with the PGD 2 DP1 receptor antagonist BW 868C and the PPARg-antagonist GW 9662. Neither antagonist affected the induction of apoptosis of non-CD40 L -stimulated CLL cells (Figures 4b and  c) . CD40 L -stimulated proliferation tended to be inhibited by BW 868C and promoted by GW 9662 and these effects were reflected in control and treatment groups (Figures 4b and c) . However, the effects were small and did not reach significance. Neither antagonist affected the pro-apoptotic or anti-proliferative activities of exogenously added PGD 2 or 15dD 12,14 PGJ 2 . Collectively these data imply that the activities of BEZ and MPA against CLL cells are not significantly mediated via either PGD 2 DP1 receptor or PPARg.
The observation that MPA did not result in -PGD 2 elevation when used alone or in combination with BEZ was unexpected, since both western blot and quantitative real-time reverse transcription-PCR readily identified AKR1C3 expression in all CLL cells and at levels similar to those seen in the myeloid cell line K562 (Figure 5a) . Furthermore, the 11b-PGD 2 ketoreductase activity attributed to AKR1C3 was undetectable in CLL cells, although it is readily demonstrated in K562 cells (Figure 5b ). This lack of AKR1C3-associated 11b-PGD 2 ketoreductase 17 Furthermore, they demonstrated that 15dD 12, 14 PGJ 2 -induced apoptosis was associated with induction of ROS and MSO. They did not however investigate whether PGD 2 , the precursor of 15dD 12, 14 PGJ 2 , also produces elevated ROS.
As shown in Figure 6a , treatment of non-CD40 L -stimulated and CD40 L -stimulated-CLL cells with either PGD 2 or 15dD 12, 14 PGJ 2 resulted in near identical generation of ROS. Furthermore, similar ROS activation was seen in response to BEZ, MPA and BEZ þ MPA. Although it is possible to surmise that ROS generation in response to BEZ and BEZ þ MPA may be the consequence of PGD 2 and thus 15dD increased MSO in CD40 L -stimulated cells this was attenuated in comparison to non-stimulated cells. MSO also became detectable in BEZ, MPA and BEZ þ MPA treated non-CD40 L -stimulated CLL cells but not in CD40 L -stimulated cells. These data imply that CD40-ligation protects CLL cells against prostaglandin and drug-induced MSO production.
Activity of BEZ and MPA in combination with chlorambucil
As highlighted in the introduction, chemotherapy for CLL has been primarily based on alkylating agents such as chlorambucil. Therefore, we compared the actions of BEZ and MPA with that of chlorambucil in our assays. Strikingly in the absence of CD40 L the proapoptotic actions of BEZ or MPA alone were similar to that of chlorambucil (P ¼ 0.99 for both) (Figure 7a) . Apoptosis was enhanced when chlorambucil was combined with BEZ or MPA, although this did not reach significance (P ¼ 0.35 and 0.87, respectively). The incorporation of BEZ þ M-PA with chlorambucil did not generate significantly more apoptosis than BEZ þ MPA alone (P ¼ 0.852); however, this combination was significant over chlorambucil alone (P ¼ 0.013).
Chlorambucil treatment was markedly antiproliferative against CD40 L -stimulated CLL cells and this effect was enhanced by BEZ, MPA and BEZ þ MPA (P ¼ o0.001 for all) (Figure 7b) . However, the antiproliferative activities of either chlorambucil and BEZ or chlorambucil and MPA were equipotent as the combination of all three. As we have already shown for BEZ, MPA and BEZ þ MPA, the antiproliferative activity mediated by chlorambucil on CD40 L -stimulated CLL cells was not associated with enhanced apoptosis (Figure 7b ). Indeed, in these cells no combination of the above treatments induced apoptosis.
Discussion
New drug discovery is time consuming, expensive and has low success rates. 18 However, evidence from hematological malignancies demonstrates that already available drugs can have substantial impact. Examples include the use of retinoic acid 19 and arsenic trioxide 20 in acute promyelocytic leukemia and thalidomide in multiple myeloma. 21 These paradigms illustrate that drugs not originally considered as cancer therapeutics can provide genuine benefit. Here, we have demonstrated that the lipid-lowering agent BEZ and the contraceptive MPA induced significant apoptosis of CLL cells cultured in the absence of CD40 L and that the combination induced greater apoptosis than either drug alone. In 3 of 8 samples tested, we failed to observe caspase activation despite apoptotic responses by the cells. In addition, in western blot analyses we did not always observe caspase cleavage products in CLL cells that were undergoing apoptosis (data not shown). Caspase-independent apoptosis has been reported in several cell models, including CLL 22 and it cannot be ruled out that BEZ þ MPA induces caspase-independent apoptosis in some samples. The drugs each inhibited the CD40 L -driven proliferation of CLL cells with the combination having more activity than either drug alone. In addition, the drugs had little effect on normal CD5
Àve
CD19
þ ve peripheral blood B cells, indicating that these agents have a tumor cellspecific effect. The actions of BEZ when used alone or in combination with MPA were associated with marked elevations of PGD 2 as predicted for an agent that induces ROS through the lipid peroxidation-dependent isoprostane pathway. Furthermore, addition of either PGD 2 in adult T-cell leukemia cells, and thereby increased their apoptotic response to tumor necrosis factor-related apoptosisinducing ligand. 35 However, the data shown here and our studies in AML indicate that similar elevation of 15dD 12, 14 PGJ 2 can be achieved using a drug that is already available. It is important to note that the standard dose of BEZ (400 mg Bezalip Mono once daily) used to regulate lipid levels is associated with plasma levels of 25 mM. Although the doses used here to exert the proapoptotic and antiproliferative actions of BEZ exceed this by 20-fold, experience of overdose in humans and rhesus monkeys indicates that 30 times the standard daily dose is tolerated without ill effect, for up to a year. 36 On a cautionary note, it has been demonstrated that elevated lipoprotein lipase is a poor risk factor in CLL, 37 that the lipoprotein lipase-inhibitor orlistat induces apoptosis of CLL cells in vitro 38 and that BEZ elevated lipoprotein lipase in hypertriglyceridemic patients during BEZ administration. 39 Medroxyprogesterone acetate has been used to treat breast and renal cell cancers. The doses used in these settings (up to a 1000 mg/day) achieve plasma levels up to 15 mM. Thus, the doses used in our experiments are commensurate with those achievable in patients. Unexpectedly, however, the actions of MPA on CLL cells did not appear to be mediated through enhanced PGD 2 synthesis. Nevertheless, MPA did contribute to ROS and MSO generation in CLL cells and exerted both proapoptotic and antiproliferative effects independently of BEZ. Thus, a challenge for future study is to elucidate this mechanism. Other known targets of MPA include glucocorticoid, androgen and progesterone receptors [40] [41] [42] but control experiments using ligands and antagonists of these receptors failed to mimic or abrogate the effect of MPA on CLL cells, therefore it is unlikely that these are the targets (data not shown). Others have identified that MPA enhances anthracyclin uptake by CLL cells and increases apoptosis of cultured CLL cells exposed to the anthracyclin idarubicin. 43, 44 These observations are possibly explained by the chemosensitizing actions of MPA acting as an inhibitor of the ATP-binding cassette drug resistance transporter p-glycoprotein (MDR1). 45 Future studies will address whether the role of MPA in enhancing the effect of BEZ on CLL cells is similarly mediated by inhibition of p-glycoprotein or other ATP-binding cassette drug resistance transporters.
Although not normally considered as anticancer drugs, BEZ þ MPA was as potent in our assays as the established CLL drug chlorambucil. This combined with the relatively low toxicity profiles of BEZ and MPA renders it plausible to consider their use in the treatment of CLL patients' refractory to other treatments. In this regard, we have observed BEZ þ MPA to be well tolerated in a pilot phase I/II study of elderly and frail AML patients and have observed strong indications of potential clinical benefit (Khanim et al., 2008, unpublished data). Although the overall response rate of CLL cells to BEZ, MPA and BEZ þ MPA was high, there was nonetheless some underlying heterogeneity. This heterogeneity did not appear to correlate with acknowledged prognostic variables (stage, LDT, ZAP-70, CD38, genetics and IgVH). Thus, at this stage it is uncertain whether there is a particular subset of CLL patients that may benefit from BEZ þ MPA. However, the assays we have developed in this study could be used to identify whether in vitro responses are predictive of in vivo responses. Finally, BEZ þ MPA when combined with chlorambucil showed greater proapoptotic and antiproliferative effects than either BEZ þ MPA or chlorambucil alone. Therefore, the work presented in this study provides evidence that BEZ þ MPA represents a novel, readily accessible therapy for treatment of CLL either alone or in combination with other therapies. 
